In this study, primary tumors’ fluorine-18-fluorodeoxyglucose (18F-FDG) uptake in luminal A, luminal B, triple-negative, and human epidermal growth factor receptor type-2 subtypes of breast cancer was evaluated. In addition, the relationship between the primary tumor maximum standardized uptake value (SUVmax) value and the presence of distant metastasis and axillary involvement was evaluated.
Whole-body 18F-FDG PET/computed tomography (CT) imaging of 493 patients (mean age; 54.6±13.2 years) diagnosed with primary breast cancer were analyzed retrospectively. PET/CT imaging was obtained 60 min after the intravenous administration of 18F-FDG. 18F-FDG uptake of the lesions was assessed by calculating the SUVmax. Histopathological analyses were carried out on the basis of biopsy samples before PET/CT. For histopathological staging, the Scarff Bloom Richardson classification system was utilized, and patients were classified into luminal A, luminal B, triple-negative, and human epidermal growth factor receptor type-2 molecular subtypes.
82.9% of the patients had invasive ductal carcinoma, 5.8% had invasive lobular carcinoma, 4.2% had apocrine carcinoma, 3.8% had mucinous carcinoma, and 3.4% has mixed carcinoma. Although the highest mean SUVmax was calculated in apocrine tumors (12.4±7.2), the lowest mean SUVmax was calculated in lobular carcinoma (6.8±4.6), and a statistically significant difference was found between the histological groups (P<0.001). 18F-FDG uptake was reported to be significantly higher in the triple-negative subtype than the luminal types, and in the luminal B subtype than the luminal A subtype. A statistically significant relation was found between primary tumor SUVmax and distant nodal, organ metastasis (P=0.003 and <0.001, respectively).
Increased primary tumor 18F-FDG uptake was associated with aggressive molecular subtypes in this study. The relationship of distant nodal and organ metastasis with primary tumor SUVmax showed that increased 18F-FDG uptake is important in terms of management of therapy and prognosis.
Departments of aNuclear Medicine
cPathology, Istanbul Training and Research Hospital
dDepartment of Pathology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
Correspondence to Esra Arslan, MD, Istanbul Egitim ve Arastirma Hastanesi, Nukleer Tip Kliniği, Org. Nafiz Gurman Caddesi, Samatya, Kocamustafapasa, Fatih, Istanbul 34103, Turkey Tel: +90 212 459 64 55; fax: +90 212 632 63 29; e-mail: email@example.com
Received January 18, 2018
Received in revised form April 2, 2018
Accepted April 8, 2018